

# *Staphylococcus aureus* Colonization in Acute and Chronic Skin Lesions of Patients with Atopic Dermatitis

Hae-Young Park, Cho-Rok Kim, Ik-Soo Huh<sup>1</sup>, Mi-Young Jung, Eun-Young Seo<sup>2</sup>, Ji-Hye Park, Dong-Youn Lee, Jun-Mo Yang

Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine,

<sup>1</sup>Department of Statistics, <sup>2</sup>Institute of Dermatological Science, Medical Research Center, Seoul National University, Seoul, Korea

**Background:** *Staphylococcus aureus* (SA) has peculiar abilities to colonize the skin in atopic dermatitis (AD) patients. **Objective:** We sought to determine the colonization rates of SA in acute and chronic skin lesions of AD patients, to find any difference in colonization rates according to age and to find the influences of total immunoglobulin E (IgE) and eosinophil counts to the colonization of SA. **Methods:** We evaluated the total IgE level and eosinophil counts, and cultured SA from the skin lesions of 687 AD patients (131 acute and 556 chronic skin lesions) and 247 control urticaria patients (July 2009 to November 2010; Samsung Medical Center Dermatology Clinic, Seoul, Korea). **Results:** The SA colonization rates were 74%, 38% and 3% in acute, chronic skin lesions and control skin, respectively, and they were increased with age in AD patients. The colonization rate in chronic skin lesions was higher in the high IgE/eosinophilia groups as compared to the normal IgE/eosinophil groups. **Conclusion:** The SA colonization rate was higher in AD patients and especially in acute lesions, and had a tendency to increase with age. As the colonization rates were only higher in the high IgE/eosinophilia groups of chronic skin lesions, we suggested that SA may invade the skin through barrier defects in acute skin lesions, but the

colonization in chronic lesions may be orchestrated through many different factors. (**Ann Dermatol 25(4) 410~416, 2013**)

## **-Keywords-**

Atopic dermatitis, Colonization rate, Eosinophil counts, Serum total IgE, *Staphylococcus aureus*

## **INTRODUCTION**

Atopic dermatitis (AD) is a chronic inflammatory skin disease and it has been classified into two different subtypes; classic age-matched subtyping (infantile, childhood, and adult) and presence/absence of allergy (extrinsic AD and intrinsic AD). Lesions can be classified as acute or chronic according to the skin status and differences in cytokine expressions of the lesional skin.

In addition to the presence or absence of sensitization to allergens, AD patients often have impaired skin barrier functions, display significant decreases in the expressions of antimicrobial peptides (AMP) and exhibit innate immune defects, which explain their increased susceptibility to secondary skin infections due to bacteria, fungi or viruses.

Of all the infectious agents found to affect AD patients, the best-characterized is *Staphylococcus aureus*. The prevalence of *S. aureus* skin colonization in healthy individuals is 5% to 30%, while 75% to 100% of AD patients have *S. aureus* on their lesional skin and 30% to 100% of AD patients have this bacteria on their nonlesional skin<sup>1-4</sup>. A correlation between the severity of eczema and colonization with *S. aureus* has been demonstrated, which means that bacterial colonization is an important mechanism in the aggravation of skin lesions<sup>3,5</sup>. Despite the conflicting data, several studies have demonstrated that treatment of *S. aureus* can decrease the severity of eczema

Received April 27, 2012, Revised August 3, 2012, Accepted for publication September 1, 2012

**Corresponding author:** Jun-Mo Yang, Department of Dermatology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-3541, Fax: 82-2-3410-3869, E-mail: junmo.yang@samsung.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

in AD patients<sup>6,7</sup>. Subjects with severe AD are considered to be more susceptible to *S. aureus* colonization because they have both innate and adaptive immune defects<sup>8</sup>.

Th2 polarity with excess production of Th2 cytokines (interleukin [IL]-4, IL-5 and IL-13) may be a key factor in the epithelial production of fibronectin and fibrinogen, which can act as substrates for *S. aureus* adherence<sup>9</sup>. There is growing evidence suggesting that this Th2 polarity may adversely affect the innate immune response in the skin of AD patients by inhibiting the productions of AMP and the antimicrobial chemokine MIP3  $\alpha$  (CCL20)<sup>10,11</sup>. Additionally, increased levels of Th2 cytokines inhibit the keratinocyte mobilization of HBD-3<sup>12</sup>. Therefore, biomarkers for Th2 polarity such as serum total immunoglobulin E (IgE) and eosinophil counts can be associated with *S. aureus* superinfection. Warner et al.<sup>13</sup> reported that there was a significantly higher IgE level and greater number of eosinophils in patients with *S. aureus* colonization than in patients without colonization.

We evaluated laboratory parameters including serum IgE and blood eosinophil counts, and also cultured *S. aureus* from the skin lesions of AD patients and from the control urticaria patients. We reviewed our data to determine (1) the colonization rates of *S. aureus* in acute and chronic skin lesions of AD patients and compared them with those of non-AD patients for (2) whether there are differences in the colonization rates according to age, (3) whether Th2 polarity markers (serum total IgE and eosinophil counts) can influence the colonization rates of *S. aureus* in different age groups and different lesional states.

## MATERIALS AND METHODS

### Patients

We recruited 687 AD patients (188 infants, 267 children, and 232 adults; 131 acute skin lesions and 556 chronic skin lesions) and 247 control urticaria patients without any skin lesions, including AD or psoriasis, from July 2009 to November 2010. All the patients were examined at the Samsung Medical Center (Seoul, Korea) Dermatology Clinic. Subjects with clinically obvious infections such as impetigo, furuncles or cellulitis were excluded. All the participants did not take any medication during the past 2 weeks. The demographic information is summarized in Table 1.

This study was conducted according to the Declaration of Helsinki, and written informed consent was obtained from all participants. The Samsung Medical Center Ethics Committee approved this study (IRB 2009-12-053-006).

### Laboratory markers

Serum total IgE level and blood eosinophil count were measured for all subjects with AD and the control patients. Serum total IgE were measured by ImmunoCAP<sup>TM</sup> fluorescence enzyme linked assay (Phadia AB, Uppsala, Sweden) and blood eosinophil counts by XE-2100 laser optical flow cytometry (Sysmex Corp., Kobe, Japan). Threshold levels indicative of significances were defined as follows: serum total IgE  $\geq 100$  kU L<sup>-1</sup> for the infant group, and  $\geq 200$  kU L<sup>-1</sup> for the child and adult groups, and total eosinophil count  $\geq 300$  cells mm<sup>-3</sup> for the infant group, and  $\geq 500$  cells mm<sup>-3</sup> for the child and adult groups.

**Table 1.** Patient demographics

| Variable         | Atopic dermatitis patients |                            |                            |                           | Urticaria patients        |
|------------------|----------------------------|----------------------------|----------------------------|---------------------------|---------------------------|
|                  | Infant                     | Child                      | Adult                      | Total                     |                           |
| Patient (n)      | 188                        | 267                        | 232                        | 687                       | 247                       |
| Gender           |                            |                            |                            |                           |                           |
| Male (n)         | 107                        | 138                        | 114                        | 359                       | 97                        |
| Female (n)       | 81                         | 129                        | 118                        | 328                       | 150                       |
| Age (yr)         |                            |                            |                            |                           |                           |
| Mean (SD)        | 1.22 (0.96)                | 9.97 (4.34)                | 26.50 (7.33)               | 13.12 (11.20)             | 43.56 (14.67)             |
| Median (range)   | 1.0 (0.3~2.9)              | 10.0 (3.2~17.7)            | 25.0 (18.0~56.0)           | 11.0 (0.3~56.0)           | 42.8 (18.0~88.1)          |
| IgE              |                            |                            |                            |                           |                           |
| Mean (SD)        | 177.83 (551.02)            | 694.43 (1,150.11)          | 1402.80 (1,756.23)         | 790.80 (1,364.60)         | 229.39 (407.73)           |
| Median (range)   | 36.20<br>(0.00~5,001.00)   | 213.00<br>(5.00~5,001.00)  | 557.00<br>(0.00~5,001.00)  | 163.50<br>(0.00~5,001.00) | 116.00<br>(2.04~4,207.00) |
| Eosinophil level |                            |                            |                            |                           |                           |
| Mean (SD)        | 542.30 (524.91)            | 480.90 (575.41)            | 392.40 (377.42)            | 468.10 (505.69)           | 179.51 (197.16)           |
| Median (range)   | 382.00<br>(0.00~4,772.00)  | 354.00<br>(30.00~5,544.00) | 298.00<br>(29.00~2,684.00) | 346.00<br>(0.00~5,544.00) | 122.54<br>(0.00~1,755.00) |

SD: standard deviation.

### Isolation and identification of *Staphylococcus aureus* from atopic dermatitis skin

Subjects with clinically obvious infections, such as impetigo, furuncles or cellulitis, were excluded. We classified the lesions of AD patients into acute and chronic lesions; the acute eczematous lesions were defined by erythema, crusting and oozing; and chronic lesions manifested as papules and lichenification. Bacterial cultures were performed by rubbing rayon-tipped swabs over the lesions (acute skin lesion or antecubital fossa) of the AD patients and on the intertriginous areas of the urticaria patients after cleaning with normal saline. *Staphylococcal* strains were isolated on blood agar plates and identified as *S. aureus* using a catalase test and a slide coagulase test.

#### Statistical analysis

Homogeneity of *S. aureus* colonization rates across different age groups was analyzed using the  $\chi^2$  test. Simple or multiple logistic regressions, which was developed to analyze data of binary responses, were used to test for associations of one or multiple factors of diagnostic measurements (serum total IgE level, total eosinophil count and age) and *S. aureus* colonization rates. We used the significance level of 5% and used SAS (SAS 9.2; SAS Institute, Cary, NC, USA) to conduct the statistical analysis. The 95% confidence intervals of the odds ratios were also used for calculating the results of logistic regression<sup>14</sup>.

## RESULTS

### Patterns of *Staphylococcus aureus* colonization

There was a statistically significant difference in *S. aureus* colonization rates of AD patients and controls with urticaria ( $p \leq 0.0001$ ). Colonization rates were 74.0% (97/131) in acute skin lesions of AD patients, 37.9%

(211/556) in chronic lesions of AD patients, and 3.2% (8/247) in urticaria patients (Table 2).

When we compared the *S. aureus* colonization rates in different age groups, we also observed statistically significant differences in both acute and chronic lesions of AD patients (Table 2). The colonization rates in the infant, child, and adult groups were 50.0% (18/36), 80.0% (44/55) and 87.5% (35/40), respectively, for acute skin lesions, and 18.5% (28/151), 41.8% (90/215) and 48.9% (93/190) for chronic skin lesions. This revealed a tendency for the *S. aureus* colonization rate to increase with age ( $\chi^2$  test, acute lesions:  $p = 0.0004$ ; chronic lesions:  $p \leq 0.0001$ ).

### The influences of elevated serum total immunoglobulin E level and the presence of eosinophilia on *Staphylococcus aureus* colonization rate in atopic dermatitis patients

As serum total IgE levels and eosinophil counts have been reported to influence the *S. aureus* colonization<sup>13</sup>, we also compared the *S. aureus* colonization rates according to those parameters. When comparing the colonization results of the elevated serum total IgE group and the normal serum total IgE group, the AD patients in the elevated serum IgE group showed higher *S. aureus* colonization rates than the normal serum total IgE group with acute and chronic skin lesions. However, the correlation was statistically less significant in acute skin lesions (acute lesion: 81.1% vs. 64.9%,  $p = 0.0387$ ; chronic lesion: 52.8% vs. 23.9%,  $p \leq 0.0001$ ). Although the number of *S. aureus*-positive patients in the urticaria group was small, the elevated total IgE group did not have increased *S. aureus* colonization rates. Nevertheless, the urticaria patients with elevated total IgE showed decreased *S. aureus* colonization rates when compared to the normal total IgE group (Table 3A).

When we compared the colonization results according to the eosinophil counts in the chronic lesion group, the patients with eosinophilia showed significantly increased

**Table 2.** *Staphylococcus aureus* colonization rates in each age group of patients

| Age category (yr)          | <i>Staphylococcus aureus</i> colonization |                |                            | Urticaria patients |
|----------------------------|---|----------------|----------------------------|--------------------|
|                            | Acute lesion                              | Chronic lesion | 95% CI of OR ( $p$ -value) |                    |
| Infants (<2)               | 18/36 (50.0)                              | 28/151 (18.5)  | 0.105~0.492 (0.0002)       |                    |
| Children ( $\geq 3$ , <18) | 44/55 (80.0)                              | 90/215 (41.8)  | 0.088~0.398 (<0.0001)      |                    |
| Adults ( $\geq 18$ )       | 35/40 (87.5)                              | 93/190 (48.9)  | 0.051~0.365 (<0.0001)      | 8/247 (3.2)        |
| Total                      | 97/131 (74.0)                             | 211/556 (37.9) | 0.139~0.328 (<0.0001)      | 8/247 (3.2)        |
| $\chi^2$ test $p$ -value*  | 0.0004                                    | <0.0001        |                            |                    |

Values are presented as number (%). CI: confidence interval, OR: odds ratio. \*Homogeneity test for *S. aureus* colonization rate across age groups.

*S. aureus* colonization rates as compared to those without eosinophilia (52.3% vs. 32.6%,  $p \leq 0.0001$ ). However, in the acute lesion and urticaria groups, we did not find any

statistically significant differences in *S. aureus* colonization rates according to the presence of eosinophilia (acute lesion: 71.8% vs. 77.4%,  $p = 0.477$ ; urticaria: 0%

**Table 3.** *Staphylococcus aureus* colonization rates according to the status of (A) serum total immunoglobulin E and (B) eosinophil counts

| Variable                        | <i>Staphylococcus aureus</i> colonization rate |                       |                       |                        |
|---------------------------------|--|-----------------------|-----------------------|------------------------|
|                                 | Acute lesion                                   | Chronic lesion        | Total                 | Urticaria              |
| (A)                             |  |                       |                       |                        |
| Elevated serum total IgE        | 60/74 (81.1)                                   | 143/271 (52.8)        | 203/345 (58.8)        | 1/178 (0.6)            |
| Normal serum total IgE          | 37/57 (64.9)                                   | 68/285 (23.9)         | 105/342 (30.7)        | 7/69 (10.1)            |
| 95% CI of OR ( <i>p</i> -value) | 1.04 ~ 5.14 (0.0387)                           | 2.48 ~ 5.12 (<0.0001) | 2.36 ~ 4.42 (<0.0001) | 0.006 ~ 0.415 (0.0055) |
| (B)                             |  |                       |                       |                        |
| Eosinophilia                    | 56/78 (71.8)                                   | 79/151 (52.3)         | 135/219 (61.6)        | 0/15 (0)               |
| No eosinophilia                 | 41/53 (77.4)                                   | 132/405 (32.6)        | 173/468 (37.0)        | 8/232 (3.4)            |
| 95% CI of OR ( <i>p</i> -value) | 0.33 ~ 1.68 (0.477)                            | 1.57 ~ 3.36 (<0.0001) | 1.86 ~ 3.60 (<0.0001) | 0 ~ ∞ (0.993)          |

Values are presented as number (%) or range (*p*-value). IgE: immunoglobulin E, CI: confidence interval, OR: odds ratio.

**Table 4.** *Staphylococcus aureus* colonization rates in acute (A) and in chronic (B) lesions of atopic dermatitis patients (combined effect of elevated serum total immunoglobulin E and eosinophilia)

| Variable                                     | <i>Staphylococcus aureus</i> colonization rates in acute lesions of atopic dermatitis patient |                      |                     |                       |
|--|---|----------------------|---------------------|-----------------------|
|  | Infant  | Child                | Adult               | Total                 |
| (A)  |   |                      |                     |                       |
| Elevated serum total IgE and eosinophilia    | 5/13 (38.5)   | 20/24 (83.3)         | 12/12 (100.0)       | 37/49 (75.5)          |
| Elevated serum total IgE and no eosinophilia | 1/1 (100.0)   | 8/8 (100.0)          | 14/16 (87.5)        | 23/25 (92.0)          |
| Normal serum total IgE and eosinophilia      | 11/20 (55.0)  | 6/7 (85.7)           | 2/2 (100.0)         | 19/29 (65.5)          |
| Normal serum total IgE and no eosinophilia   | 1/2 (50.0)  | 10/16 (62.5)         | 7/10 (70.0)         | 18/28 (64.3)          |
| 95% CI of OR ( <i>p</i> -value)              |   |                      |                     |                       |
| Elevated serum IgE                           | 0.16 ~ 2.45 (0.506)   | 0.64 ~ 13.61 (0.163) | 0.40 ~ 22.3 (0.283) | 0.65 ~ 3.78 (0.319)   |
| Eosinophilia                                 | 0.04 ~ 5.90 (0.566)   | 0.24 ~ 4.87 (0.920)  | 0 ~ ∞ (0.995)       | 0.55 ~ 4.40 (0.411)   |
| Age  |   |                      |                     | 1.51 ~ 6.33 (0.00208) |

| Variable                                     | <i>Staphylococcus aureus</i> colonization rates in chronic lesions of atopic dermatitis patient |                       |                        |                       |
|--|---|-----------------------|------------------------|-----------------------|
|  | Infant  | Child                 | Adult                  | Total                 |
| (B)  |   |                       |                        |                       |
| Elevated serum total IgE and eosinophilia    | 3/12 (25.0)   | 29/50 (58.0)          | 25/33 (75.8)           | 57/95 (60.0)          |
| Elevated serum total IgE and no eosinophilia | 4/24 (16.7)   | 31/61 (50.8)          | 51/91 (56.0)           | 86/176 (48.9)         |
| Normal serum total IgE and eosinophilia      | 14/41 (34.1)  | 6/11 (55.6)           | 2/4 (50.0)             | 22/56 (39.3)          |
| Normal serum total IgE and no eosinophilia   | 7/74 (9.5)  | 24/93 (25.8)          | 15/62 (24.2)           | 46/229 (20.0)         |
| 95% CI of OR ( <i>p</i> -value)              |   |                       |                        |                       |
| Elevated serum IgE                           | 0.42 ~ 3.01 (0.815)   | 1.33 ~ 4.45 (0.00394) | 1.98 ~ 7.65 (7.78e-05) | 1.67 ~ 3.65 (<0.0001) |
| Eosinophilia                                 | 1.60 ~ 8.79 (0.00241)   | 0.88 ~ 3.32 (0.10791) | 1.12 ~ 5.83 (0.0264)   | 1.57 ~ 3.70 (<0.0001) |
| Age  |   |                       |                        | 1.40 ~ 2.36 (<0.0001) |

Values are presented as number (%) or range (*p*-value). IgE: immunoglobulin E, CI: confidence interval, OR: odds ratio.

vs. 3.4%,  $p=0.993$ ) (Table 3B).

**The combined effects of elevated serum total immunoglobulin E and eosinophilia on *Staphylococcus aureus* colonization rate in atopic dermatitis patients with acute lesions**

As serum total IgE or eosinophilia alone showed a significant result only in the chronic skin lesion group, we analyzed the combined effects of elevated serum total IgE level and eosinophilia according to *S. aureus* colonization rate (Table 4). We classified the patients into four groups: the first group had elevated serum total IgE with eosinophilia, the second group had elevated serum total IgE without eosinophilia, the third group had eosinophilia with normal serum IgE, and the fourth group had normal serum IgE and no eosinophilia.

In the acute skin lesion group, the colonization rates of *S. aureus* of AD patients in the four groups were 75.5% (37/49), 92.0% (23/25), 65.5% (19/29) and 64.3% (18/28), respectively, and there were no statistically significant differences among these groups (Table 4A, Fig. 1A). We also tested these two parameters to the *S. aureus* colonization rates of AD patients in the different age groups via multiple logistic regressions and found influential effects on *S. aureus* colonization among the age groups ( $p=0.00208$ ).

Although we did not detect any statistical significance between these two laboratory parameters and *S. aureus* colonization in acute skin lesions, we observed a tendency for the *S. aureus* colonization rate to increase with age.


**The combined effects of elevated serum total immunoglobulin E level and eosinophilia on *Staphylococcus aureus* colonization rate in atopic dermatitis patients with chronic lesions**

In chronic skin lesions of AD patients, the colonization rates of *S. aureus* in the four groups were 60.0% (57/95), 48.9% (81/176), 39.3% (22/56), and 20.0% (46/229), respectively, and there were significant intergroup differences (Table 4B, Fig. 1B). These data revealed that either serum total IgE or eosinophilia can affect the *S. aureus* colonization as shown in Table 3, and these two parameters showed additive effects on *S. aureus* colonization in chronic skin lesions of AD patients.

We then compared our results according to age groups. The results for the four groups were 25.0%, 16.7%, 34.1% and 9.5% in infants; 58.0%, 50.8%, 55.6% and 25.8% in children; and 75.8%, 56.0%, 50.0%, and 24.2% in adults. According to these results, only the adult group showed similar results to those of total chronic AD skin lesion.

**DISCUSSION**

*S. aureus* is a well-known, Gram-positive bacteria, and the prevalence of *S. aureus* skin colonization in healthy individuals is 5% to 30%<sup>1-4</sup>, and those in AD patients is much higher for lesional and nonlesional skin. Acute skin lesions of AD are colonized with greater numbers of *S. aureus* than the chronic nonlesional skin<sup>2</sup>, and the density of *S. aureus* has been shown to be correlated with the degree of cutaneous inflammation and the severity of the AD lesion<sup>3</sup>. We measured the *S. aureus* skin colonization



**Fig. 1.** *Staphylococcus aureus* colonization rates of atopic dermatitis patients according to serum total immunoglobulin (IgE) and eosinophilia (Eo) statuses. We drew a plot for *S. aureus* colonization rates according to the combined level of two factors. Therefore, there are four categories among samples. Values of colonization rates are from colonization rates from (A) acute lesion and (B) chronic lesion combined with serum total IgE and eosinophil counts. In chronic lesions, we can see clearly decreasing patterns of colonization rates as the level of each factor is decreasing while there are weakly decreasing patterns in acute lesions.

rate for Korean AD patients and confirmed that our results were similar to previous data. AD patients with acute skin lesions showed a higher colonization rate (74%) than AD patients with chronic skin lesions (38%). We also found that the *S. aureus* colonization rates were increased with age in both lesions of AD. A previous study conducted in Sri Lanka showed that the *S. aureus* colonization rates in acute lesions were higher with ages (47%, <1 year vs. 75%, >15 years)<sup>15</sup>. However, this study did not observe any differences in the *S. aureus* colonization rates for chronic lesions among the different age groups.

*S. aureus* colonization rates in AD patients can be affected not only by lesional state and age, but also by disease severity and duration<sup>3,5,15</sup>. As nasal *S. aureus* carriage of caregivers can be a potential source of re-colonization in children with AD<sup>16</sup>, factors such as school status and family size which can affect the nasal carriage status of *S. aureus* should also be considered<sup>17</sup>. In our study, as most of our patients lived in Seoul and suburban areas with high socioeconomic status, we did not take into account the various factors that affect *S. aureus* colonization except for lesional state and age.

The observed differences in the colonization rates of *S. aureus* among acute and chronic skin lesions in AD and controls led us to consider the factors affecting the colonization rates of *S. aureus* and whether the rates may represent an infection or simple colonization of *S. aureus* in the human skin. Many factors are related to the skin barriers, whether innate and adaptive immune defects have been reported to promote *S. aureus* colonizations in AD patients. These contributing factors include defective lipid layers, exposed extracellular matrix adhesins, changes in the immune response, bacterial superantigens and increased specific IgE production<sup>18</sup>. Compared with psoriatic skin lesions and healthy skins, one study found that the expressions of inducible AMP HBD-2 and LL-37 were significantly decreased in AD skin lesions<sup>19</sup>. The cells of AD patients are unable to efficiently mobilize the HBD-3 to kill *S. aureus*<sup>12</sup>. Recently, nonlesional skin of AD patients was shown to have impairments of tight junction proteins, and this may be partially mediated by reduction in the claudin-1 gene<sup>20</sup>. An IgE reactive protein to *S. aureus* and *S. aureus* fibronectin-binding protein (FBP) was identified in the sera of AD patients, and more than one-third of the AD patients showed specific IgE reactivity to FBP<sup>21</sup>. AD patients have been known to produce IgE-specific antibodies to staphylococcal enterotoxin A or B; however, it was recently reported that *S. aureus* produces extracellular vesicle (EV) like Gram-negative bacteria<sup>22</sup>. EV isolated from skin lavage fluids of AD patients contained *S. aureus* EV-specific proteins, and

serum *S. aureus* EV-specific IgE levels were significantly higher in AD patients than in age-matched controls<sup>23</sup>.

In this study, we found that the *S. aureus* colonization rate was higher in the high serum IgE/eosinophilia group as compared to those in the normal IgE/normal eosinophil group in chronic skin lesions but not in acute skin lesions and control group. These two parameters may work additively or synergistically on the colonization of *S. aureus*, especially in adult patients (Table 4B, Fig. 1B). It might be possible to use these two parameters as predictive markers for *S. aureus* colonization in chronic skin lesions of AD, however, this result is against previous cytokine reports (Th1 in chronic skin and Th2 in acute skin lesions)<sup>24,25</sup>.

Our data suggests that, in acute lesions of AD patients, there is a more direct damage to the epidermal skin barrier, mainly through scratching, and *S. aureus* can easily penetrate or invade the skin and feed off skin exudates. However, in chronic skin lesions of AD, the defects in tight junctions of the lesional skin and *S. aureus* FBP or *S. aureus* EV may contribute to the survival of *S. aureus* in the lesions.

In conclusion, we found that the *S. aureus* colonization rate was higher in AD patients as compared with non-AD patients, the colonization rate was even higher in acute lesions of AD patients than in chronic lesions, and the *S. aureus* colonization rate has a tendency to increase with age regardless of lesional status. As the *S. aureus* colonization rate was higher in the high serum IgE group/eosinophilia group in chronic skin lesions but not in acute skin lesions, we suggest that *S. aureus* can invade the skin through barrier defects in acute skin lesions of AD. But, the *S. aureus* colonization in chronic skin lesions of AD patients can be orchestrated through many different factors including tight junction defects in the skin and *S. aureus* FBP or *S. aureus* EV formation.

## ACKNOWLEDGMENT

This work was funded by a grant (A121406: J-M Yang) from Korean Health Technology R & D Project, Ministry of Health and Welfare, Republic of Korea, and a grant (C-A6-216-3) from Samsung Biomedical Research Institute.

## REFERENCES

1. Breuer K, HAussler S, Kapp A, Werfel T. Staphylococcus aureus: colonizing features and influence of an antibacterial treatment in adults with atopic dermatitis. *Br J Dermatol* 2002;147:55-61.
2. Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, et al. Skin colonization by Staphylococcus aureus in patients with

- eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. *Br J Dermatol* 2006;155:680-687.
3. Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. *Int J Dermatol* 1999;38:265-269.
  4. Lin YT, Wang CT, Chiang BL. Role of bacterial pathogens in atopic dermatitis. *Clin Rev Allergy Immunol* 2007;33:167-177.
  5. Guzik TJ, Bzowska M, Kasprowicz A, Czerniawska-Mysik G, Wójcik K, Szmyd D, et al. Persistent skin colonization with *Staphylococcus aureus* in atopic dermatitis: relationship to clinical and immunological parameters. *Clin Exp Allergy* 2005;35:448-455.
  6. Huang JT, Abrams M, Tloughan B, Rademaker A, Paller AS. Treatment of *Staphylococcus aureus* colonization in atopic dermatitis decreases disease severity. *Pediatrics* 2009;123:e808-e814.
  7. Brockow K, Grabenhorst P, Abeck D, Traupe B, Ring J, Hoppe U, et al. Effect of gentian violet, corticosteroid and tar preparations in *Staphylococcus aureus*-colonized atopic eczema. *Dermatology* 1999;199:231-236.
  8. De Benedetto A, Agnihotri R, McGirt LY, Bankova LG, Beck LA. Atopic dermatitis: a disease caused by innate immune defects? *J Invest Dermatol* 2009;129:14-30.
  9. Cho SH, Strickland I, Tomkinson A, Fehring AP, Gelfand EW, Leung DY. Preferential binding of *Staphylococcus aureus* to skin sites of Th2-mediated inflammation in a murine model. *J Invest Dermatol* 2001;116:658-663.
  10. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. *J Immunol* 2003;171:3262-3269.
  11. Kim BE, Leung DY, Streib JE, Kisich K, Boguniewicz M, Hamid QA, et al. Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. *J Allergy Clin Immunol* 2007;119:457-463.
  12. Kisich KO, Carspecken CW, Fiéve S, Boguniewicz M, Leung DY. Defective killing of *Staphylococcus aureus* in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. *J Allergy Clin Immunol* 2008;122:62-68.
  13. Warner JA, McGirt LY, Beck LA. Biomarkers of Th2 polarity are predictive of staphylococcal colonization in subjects with atopic dermatitis. *Br J Dermatol* 2009;160:183-185.
  14. Fleiss JL, Williams JB, Dubro AF. The logistic regression analysis of psychiatric data. *J Psychiatr Res* 1986;20:195-209.
  15. Gomes PL, Malavige GN, Fernando N, Mahendra MH, Kamaladasa SD, Seneviratne JK, et al. Characteristics of *Staphylococcus aureus* colonization in patients with atopic dermatitis in Sri Lanka. *Clin Exp Dermatol* 2011;36:195-200.
  16. Patel GK, Wyatt H, Kubiak EM, Clark SM, Mills CM. *Staphylococcus aureus* colonization of children with atopic eczema and their parents. *Acta Derm Venereol* 2001;81:366-367.
  17. Pathak A, Marothi Y, Iyer RV, Singh B, Sharma M, Eriksson B, et al. Nasal carriage and antimicrobial susceptibility of *Staphylococcus aureus* in healthy preschool children in Ujjain, India. *BMC Pediatr* 2010;10:100.
  18. Roll A, Cozzio A, Fischer B, Schmid-Grendelmeier P. Microbial colonization and atopic dermatitis. *Curr Opin Allergy Clin Immunol* 2004;4:373-378.
  19. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. *N Engl J Med* 2002;347:1151-1160.
  20. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. *J Allergy Clin Immunol* 2011;127:773-786.
  21. Reginald K, Westritschnig K, Linhart B, Focke-Tejkl M, Jahn-Schmid B, Eckl-Dorna J, et al. *Staphylococcus aureus* fibronectin-binding protein specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for cellular immune responses. *J Allergy Clin Immunol* 2011;128:82-91.
  22. Lee EY, Choi DY, Kim DK, Kim JW, Park JO, Kim S, et al. Gram-positive bacteria produce membrane vesicles: proteomics-based characterization of *Staphylococcus aureus*-derived membrane vesicles. *Proteomics* 2009;9:5425-5436.
  23. Hong SW, Kim MR, Lee EY, Kim JH, Kim YS, Jeon SG, et al. Extracellular vesicles derived from *Staphylococcus aureus* induce atopic dermatitis-like skin inflammation. *Allergy* 2011;66:351-359.
  24. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. *J Clin Invest* 1994;94:870-876.
  25. Bratton DL, Hamid Q, Boguniewicz M, Doherty DE, Kailey JM, Leung DY. Granulocyte macrophage colony-stimulating factor contributes to enhanced monocyte survival in chronic atopic dermatitis. *J Clin Invest* 1995;95:211-218.